Immunovant, Inc. (IMVT)
31.20
-0.40
(-1.28%)
USD |
NASDAQ |
Jun 10, 16:00
31.20
0.00 (0.00%)
After-Hours: 17:35
Immunovant 1 Year Total Returns (Daily) : 94.05% for June 9, 2026
1 Year Total Returns (Daily) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical 1 Year Total Returns (Daily) Data
| Date | Value |
|---|---|
| June 09, 2026 | 94.05% |
| June 08, 2026 | 83.66% |
| June 05, 2026 | 94.19% |
| June 04, 2026 | 113.0% |
| June 03, 2026 | 101.7% |
| June 02, 2026 | 100.6% |
| June 01, 2026 | 121.3% |
| May 29, 2026 | 123.6% |
| May 28, 2026 | 137.6% |
| May 27, 2026 | 133.8% |
| May 26, 2026 | 134.0% |
| May 22, 2026 | 134.5% |
| May 21, 2026 | 136.8% |
| May 20, 2026 | 137.1% |
| May 19, 2026 | 78.84% |
| May 18, 2026 | 83.47% |
| May 15, 2026 | 97.49% |
| May 14, 2026 | 110.2% |
| May 13, 2026 | 108.6% |
| May 12, 2026 | 96.91% |
| May 11, 2026 | 107.3% |
| May 08, 2026 | 102.4% |
| May 07, 2026 | 96.11% |
| May 06, 2026 | 107.2% |
| May 05, 2026 | 82.92% |
| Date | Value |
|---|---|
| May 04, 2026 | 76.27% |
| May 01, 2026 | 70.57% |
| April 30, 2026 | 68.08% |
| April 29, 2026 | 77.07% |
| April 28, 2026 | 75.03% |
| April 27, 2026 | 94.43% |
| April 24, 2026 | 89.65% |
| April 23, 2026 | 100.1% |
| April 22, 2026 | 106.9% |
| April 21, 2026 | 95.57% |
| April 20, 2026 | 88.32% |
| April 17, 2026 | 93.40% |
| April 16, 2026 | 84.30% |
| April 15, 2026 | 77.37% |
| April 14, 2026 | 72.07% |
| April 13, 2026 | 71.12% |
| April 10, 2026 | 65.65% |
| April 09, 2026 | 72.15% |
| April 08, 2026 | 85.80% |
| April 07, 2026 | 71.02% |
| April 06, 2026 | 70.71% |
| April 02, 2026 | 49.21% |
| April 01, 2026 | 65.13% |
| March 31, 2026 | 45.35% |
| March 30, 2026 | 28.20% |
Total Return Definition
The Total return is the change in price over a specific period of time that includes dividends and distributions paid.
1 Year Total Returns (Daily) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
1 Year Total Returns (Daily) Benchmarks
| Roivant Sciences Ltd. | 162.2% |
| Summit Therapeutics, Inc. | -33.72% |
| Protagonist Therapeutics, Inc. | 90.14% |
| UroGen Pharma Ltd. | 301.4% |
| Cogent Biosciences, Inc. | 363.5% |